10,000 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Acquired by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company's stock, valued at approximately $414,000.

Several other institutional investors also recently bought and sold shares of MIRM. Jones Financial Companies Lllp increased its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the period. Legato Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 7.9% in the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock valued at $554,000 after acquiring an additional 977 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Mirum Pharmaceuticals by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock worth $421,000 after acquiring an additional 1,003 shares during the last quarter. Rhumbline Advisers increased its position in shares of Mirum Pharmaceuticals by 2.4% in the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock valued at $2,196,000 after purchasing an additional 1,236 shares during the last quarter. Finally, Swiss National Bank lifted its position in shares of Mirum Pharmaceuticals by 1.9% during the 4th quarter. Swiss National Bank now owns 70,300 shares of the company's stock worth $2,907,000 after purchasing an additional 1,300 shares during the last quarter.

Insider Activity

In related news, CEO Christopher Peetz sold 7,489 shares of the firm's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the sale, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Peter Radovich sold 1,998 shares of the company's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the transaction, the chief operating officer now owns 27,015 shares in the company, valued at $1,156,782.30. The trade was a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 133,679 shares of company stock valued at $6,007,081 in the last three months. 22.87% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright raised their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $58.20.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM traded up $1.14 during trading on Wednesday, reaching $45.18. The company's stock had a trading volume of 74,931 shares, compared to its average volume of 513,183. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The business's fifty day moving average price is $47.89 and its 200-day moving average price is $43.93. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -22.37 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). The company had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.